Mandate

Vinge advises AcadeMedia in relation to its listing on Nasdaq Stockholm

June 15, 2016

Vinge advises AcadeMedia AB (publ) and selling shareholders in relation to AcadeMedia’s listing on Nasdaq Stockholm. Trading in the AcadeMedia share on Nasdaq Stockholm commences today, June 15 2016. The price in the offering was set at SEK 40 per share, which corresponds to a value of the total number of shares in the company upon completion of the offering of SEK 3,764 million. Assuming the over-allotment option is exercised in full, the value of the offering will amount to approximately SEK 1,093 million.

AcadeMedia is the leading and single largest independent education provider in northern Europe. In 2014/15, approximately 62,000 children and students attended AcadeMedia’s preschools, compulsory schools and upper secondary schools. An additional 80,000 individuals participated in AcadeMedia’s adult education courses. In 2014/15, AcadeMedia had approximately 400 preschools, compulsory schools and upper secondary schools in Sweden and Norway and approximately 150 adult education units in Sweden. AcadeMedia also has seven preschools in the Munich region of Germany. AcadeMedia has operations throughout the education chain, from preschool, compulsory school and upper secondary school to adult education.

Vinge’s team primarily consists of Erik Sjöman, Dain Hård Nevonen, Christian Lindhé, Ludvig Frithiof, Sofie Bjärtun, Nils Fredrik Dehlin and Astrid Karlsson. Maria Schultzberg and Emelie Parland advise on tax matters.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026